Stock IONS IONIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Ionis Pharmaceuticals, Inc.

Equities

IONS

US4622221004

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-05 pm EDT 		5-day change 1st Jan Change
46.09 USD +1.07% Intraday chart for Ionis Pharmaceuticals, Inc. -3.29% -8.90%
Jun. 27 Stifel Adjusts Ionis Pharmaceuticals Price Target to $53 From $50, Maintains Hold Rating MT
Jun. 25 Ionis Pharmaceuticals' Shares Rise After FDA Accepts Metabolic Disorder Drug Candidate for Priority Review MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analyst opinion has improved significantly over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • The company is in debt and has limited leeway for investment
  • Based on current prices, the company has particularly high valuation levels.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
IONIS PHARMACEUTICALS, INC. Stock Ionis Pharmaceuticals, Inc.
-8.90% 6.72B
B+
MODERNA, INC. Stock Moderna, Inc.
+18.97% 45.34B
B-
LONZA GROUP AG Stock Lonza Group AG
+41.98% 40.42B
A
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-10.06% 37.92B
B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+31.15% 31.75B
B
CELLTRION, INC. Stock Celltrion, Inc.
-7.79% 27.71B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.32% 26.52B
B-
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+43.05% 13.96B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.28% 12.44B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.41% 11.26B
B+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. IONS Stock
  4. Ratings Ionis Pharmaceuticals, Inc.